EE644 Budget Impact Analysis of Axitinib (Caxetib®) as Second-Line Therapy for the Treatment of Metastatic Renal Cell Carcinoma in a Cohort in Mexico
Dec 1, 2024, 00:00
10.1016/j.jval.2024.10.924
https://www.valueinhealthjournal.com/article/S1098-3015(24)03787-2/fulltext
Title :
EE644 Budget Impact Analysis of Axitinib (Caxetib®) as Second-Line Therapy for the Treatment of Metastatic Renal Cell Carcinoma in a Cohort in Mexico
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)03787-2&doi=10.1016/j.jval.2024.10.924
First page :
Section Title :
Open access? :
No
Section Order :
10419